StockData
ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31

Zoetis Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$79.59+0.21 (+0.26%)

Close on Oct 19, 2026

Market cap
$33.24B
P/E (TTM)
13.1
Dividend yield
2.55%

Earnings

Next report expected Nov 3, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open$2.50B$1.65$1.87
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026Before market open$2.30B$1.42$1.53
Q4 FY2025
Ended Dec 31, 2025
Feb 12, 2026Before market open$2.40B$1.37$1.48
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025Before market open$2.40B$1.63$1.70
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025Before market open$2.50B$1.61$1.76
Q1 FY2025
Ended Mar 31, 2025
May 6, 2025Before market open$2.20B$1.41$1.48
Q4 FY2024
Ended Dec 31, 2024
Feb 13, 2025Before market open$2.30B$1.29$1.40
Q3 FY2024
Ended Sep 30, 2024
Nov 4, 2024Before market open$2.40B$1.50$1.58
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 13, 2024Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted diluted EPSnon-GAAPFull Year 2026$6.15 to $6.25Lowered
Reported diluted EPSGAAPFull Year 2026$5.55 to $5.65Lowered
Cost of sales as a percentage of revenueGAAPFull Year 202629.2%Raised
Effective tax rateGAAPFull Year 202620.6%Lowered
Adjusted cost of sales as a percentage of revenuenon-GAAPFull Year 202629%Raised
Effective tax rate on adjusted incomenon-GAAPFull Year 202620.5%Lowered
Adjusted net income organic operational resultsnon-GAAPFull Year 2026-9% to -5% growthLowered
Certain significant items and acquisition and divestiture-related costsFull Year 2026$150.00MRaised
SG&A expensesGAAPFull Year 2026$2.35B to $2.40BRaised
R&D expensesGAAPFull Year 2026$722.00M to $732.00MLowered
Interest expense and other (income)/deductions-netGAAPFull Year 2026$215.00MLowered
Adjusted SG&A expensesnon-GAAPFull Year 2026$2.33B to $2.38BLowered
Adjusted R&D expensesnon-GAAPFull Year 2026$720.00M to $730.00MLowered
Adjusted interest expense and other (income)/deductions-netnon-GAAPFull Year 2026$215.00MLowered
Organic operational resultsnon-GAAPFull Year 2026-3% to -1% growthLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Zoetis filed with the SEC